Handlungsempfehlung zur Therapieumstellung von Immunsuppressiva auf Dupilumab bei Patienten mit atopischer Dermatitis

Based on new insights into the molecular pathogenesis of atopic dermatitis, a targeted anti-inflammatory therapy—dupilumab—has recently been approved as treatment alongside glucocorticoids and ciclosporin. Due to their pharmacology, neither glucocorticoids nor ciclosporin nor the off label used subs...

Descripción completa

Detalles Bibliográficos
Autores principales: Wohlrab, Johannes, Mrowietz, Ulrich, Weidinger, Stephan, Werfel, Thomas, Wollenberg, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2020
Materias:
Übersichten
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016796/
https://www.ncbi.nlm.nih.gov/pubmed/33175219
http://dx.doi.org/10.1007/s00105-020-04720-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016796/
https://www.ncbi.nlm.nih.gov/pubmed/33175219
http://dx.doi.org/10.1007/s00105-020-04720-1

Ejemplares similares